Thomas O. Daniel

Tom has contributed to innovative healthcare solutions as a practicing physician, scientist, educator, research executive and entrepreneur. Currently Venture Partner at ARCH Venture Partners, he previously led Research & Early Development at Celgene Corporation, where he and colleagues established new corporate collaboration approaches and advanced to approval multiple impactful medicines in oncology and inflammatory diseases. Formerly in senior R&D leadership positions at Immunex, Amgen, and Ambrx, he currently Chairs Locana Bio, and serves as Director at Magenta Therapeutics, Zafgen, VIR Bio, Sana Therapeutics, and Gossamer Bio. He chairs the Board of Overseers of The Scripps Research Institute, advises Vanderbilt University Medical Center, the Parker Institute for Cancer Immunotherapy, is a Trustee of Reed College, and serves as Director for the Lupus Research Alliance. He obtained his undergraduate degree at Southern Methodist University, his medical degree at UT-Southwestern Medical School, trained in Internal Medicine at Massachusetts General Hospital, and was formerly Hakim Professor of Medicine at Vanderbilt.